Inhibition of UCP2 and UCP3 increased ROS formation, reduced viability via autophagic cell death, and increased the toxic effects of chemotherapeutics in breast cancer cells while high UCP2 levels confer a poor prognosis to breast cancer patients (91). Here, UCP3 is linked to breast carcinoma.